Comparative Pharmacology
Head-to-head clinical analysis: HYDERGINE LC versus MIGRANAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDERGINE LC versus MIGRANAL.
HYDERGINE LC vs MIGRANAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
MIGRANAL (dihydroergotamine mesylate) is an ergot alkaloid with agonist activity at serotonin 5-HT1D and 5-HT1B receptors, leading to vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks.
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
1 mg intramuscularly at onset of migraine headache; may repeat after 1 hour if needed. Maximum: 2 mg per day and 4 mg per week.
None Documented
None Documented
Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing.
Terminal elimination half-life ranges from 7 to 10 hours (mean 8.5 hours). Prolonged in renal impairment.
Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%).
Primarily hepatic metabolism followed by renal excretion. Approximately 10% excreted unchanged in urine; fecal excretion accounts for <1%.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid